Medtronic named to Fortune 2026 ‘Change the World’ list for Medtronic LABS and Healthy Neighbor

Medtronic today announced it has been named to the prestigious FORTUNE 2026 'Change the World' list for its Healthy Neighbor program through Medtronic LABS. The annual list aims to showcase companies that are working to combat global issues and drive positive social or environmental change.

In partnership with Virtua Health, the Healthy Neighbor program was designed to address chronic health disparities in Camden, New Jersey. Located just across the river from Philadelphia, Camden residents face a reduction in life expectancy of nearly 16 years compared to neighborhoods just 6.5 miles away. In particular, the rates of diabetes and high blood pressure in Camden are dramatically higher than in nearby communities.

Looking to address these health disparities, local healthcare provider Virtua Health partnered with Medtronic LABS, a nonprofit funded by Medtronic. For more than a decade, Medtronic LABS has been using community-based, tech-enabled solutions to address healthcare disparities around the world. This partnership presented an opportunity to pilot this model in the United States for the first time.

"Being recognized on this list is not just an honor, but an affirmation that our work at Medtronic to put patients first in every aspect of the business is making a meaningful impact," said Ruchika Singhal, president of Medtronic LABS. "True innovation in healthcare should be comprehensive - from developing the technology itself to rethinking delivery models - and should improve health outcomes no matter your ZIP code or income."

The Healthy Neighbor program brings community health workers directly to the homes of those with high blood pressure and/or type 2 diabetes for ongoing healthcare coordination. Each team member is equipped with a digital health platform, streamlining their work by capturing basic healthcare information, tracking blood pressure and glucose over time, and flagging elevated readings for follow-up.

The first phase of Healthy Neighbor enrolled more than 250 patients, and the two-year results are remarkable:

• 74% of patients with uncontrolled hypertension achieved meaningful improvement, with an average 15-point drop in systolic blood pressure.
• 69% of patients with uncontrolled diabetes achieved a meaningful improvement with a 1.2% mean drop in A1C.
• These improvements in blood pressure and hemoglobin A1C control are linked to a significant reduction in debilitating long-term complications.¹

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

¹Uncontrolled hypertension is defined as a baseline reading ≥140/90 (n=58). Uncontrolled diabetes is defined as baseline HbA1c ≥ 8% (n=26). Meaningful improvement in blood pressure is defined as achieving blood pressure control (<140/90) or a ≥10mmHg reduction in systolic blood pressure. Meaningful improvement in HbA1c is defined as achieving control (HbA1c <8%) or ≥1% reduction in HbA1c.